Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Central Nervous System Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
52 drugs · 206 active trials
5 drugs · 33 active trials
5 drugs · 185 active trials
Outside the funnel: Phase not stated 1 · Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Temozolomide | Approved | Phase 4 | 116 | 49 | 48 | 355 | 15 | EU, US | Jan 26, 1999 | 1997-11 |
| Cyclophosphamide | Approved | Phase 3 | 26 | 17 | 11 | 58 | 1 | US | Sep 12, 2023 | 1995-05 |
| Bevacizumab | Approved | Phase 3 | 24 | 12 | 12 | 139 | 1 | US | Feb 26, 2004 | 2006-07 |
| Methotrexate | Approved | Phase 4 | 17 | 10 | 7 | 49 | 1 | US | Aug 10, 1959 | 1997-11 |
| Dordaviprone | Approved | Phase 3 | 2 | 2 | 1 | 8 | 1 | US | Aug 6, 2025 | 2014-01 |
| Pembrolizumab | Phase 4 | Phase 4 | 26 | 10 | 1 | 51 | 0 | — | — | 2013-03 |
| Trametinib | Phase 4 | Phase 4 | 2 | 0 | 0 | 4 | 0 | — | — | Dec 28, 2017 |
| Dabrafenib | Phase 4 | Phase 4 | 2 | 0 | 0 | 3 | 0 | — | — | Dec 28, 2017 |
| Firmonertinib | Phase 4 | Phase 4 | 2 | 2 | 0 | 3 | 0 | — | — | Jan 1, 2024 |
| Durvalumab | Phase 4 | Phase 4 | 1 | 0 | 0 | 6 | 0 | — | — | Feb 26, 2015 |
| Nivolumab | Phase 3 | Phase 3 | 24 | 5 | 3 | 56 | 0 | — | — | Feb 7, 2014 |
| Rituximab | Phase 3 | Phase 3 | 16 | 10 | 1 | 35 | 0 | — | — | 2002-06 |
| Lomustine | Phase 3 | Phase 3 | 15 | 7 | 15 | 48 | 0 | — | — | 2001-04 |
| Carboplatin | Phase 3 | Phase 3 | 13 | 7 | 8 | 52 | 0 | — | — | 1992-10 |
| Etoposide | Phase 3 | Phase 3 | 13 | 8 | 9 | 43 | 0 | — | — | 1995-05 |
| Vincristine | Phase 3 | Phase 3 | 12 | 5 | 10 | 34 | 0 | — | — | 1995-05 |
| Ipilimumab | Phase 3 | Phase 3 | 10 | 2 | 2 | 22 | 0 | — | — | Feb 7, 2014 |
| Dexamethasone | Phase 3 | Phase 3 | 8 | 4 | 3 | 20 | 0 | — | — | 2010-03 |
| Irinotecan | Phase 3 | Phase 3 | 7 | 2 | 1 | 31 | 0 | — | — | 1999-01 |
| Topotecan | Phase 3 | Phase 3 | 7 | 4 | 1 | 22 | 0 | — | — | 1992-10 |
| Cisplatin | Phase 3 | Phase 3 | 7 | 3 | 9 | 20 | 0 | — | — | 1995-05 |
| Metformin | Phase 3 | Phase 3 | 6 | 4 | 2 | 10 | 0 | — | — | Sep 14, 2011 |
| Niraparib | Phase 3 | Phase 3 | 6 | 0 | 1 | 10 | 0 | — | — | 2011-02 |
| Filgrastim | Phase 3 | Phase 3 | 5 | 4 | 5 | 26 | 0 | — | — | 1992-10 |
| Melphalan | Phase 3 | Phase 3 | 5 | 4 | 1 | 19 | 0 | — | — | 1998-11 |
| Thiotepa | Phase 3 | Phase 3 | 4 | 2 | 2 | 16 | 0 | — | — | 1992-10 |
| Chemotherapy | Phase 3 | Phase 3 | 4 | 3 | 3 | 13 | 0 | — | — | 2006-01 |
| Doxorubicin | Phase 3 | Phase 3 | 4 | 2 | 3 | 11 | 0 | — | — | 1997-11 |
| Everolimus | Phase 3 | Phase 3 | 3 | 3 | 1 | 12 | 0 | — | — | 2007-08 |
| Paclitaxel | Phase 3 | Phase 3 | 3 | 1 | 1 | 6 | 0 | — | — | 2007-03 |
| Regorafenib | Phase 3 | Phase 3 | 3 | 3 | 1 | 6 | 0 | — | — | 2015-11 |
| Prednisone | Phase 3 | Phase 3 | 3 | 2 | 2 | 4 | 0 | — | — | Feb 29, 2012 |
| Pegargiminase | Phase 3 | Phase 3 | 3 | 1 | 1 | 3 | 0 | — | — | Jul 30, 2019 |
| Leucovorin | Phase 3 | Phase 3 | 2 | 1 | 5 | 11 | 0 | — | — | 1997-11 |
| Ifosfamide | Phase 3 | Phase 3 | 2 | 1 | 1 | 7 | 0 | — | — | 1998-07 |
| Veliparib | Phase 3 | Phase 3 | 2 | 0 | 1 | 5 | 0 | — | — | 2009-07 |
| Safusidenib | Phase 3 | Phase 3 | 2 | 1 | 1 | 2 | 0 | — | — | Jun 5, 2023 |
| Vorasidenib | Phase 3 | Phase 3 | 2 | 1 | 1 | 2 | 0 | — | — | Jun 24, 2026 |
| Vorinostat | Phase 3 | Phase 3 | 1 | 0 | 1 | 22 | 0 | — | — | 2005-08 |
| Carmustine | Phase 3 | Phase 3 | 1 | 1 | 4 | 15 | 0 | — | — | Nov 9, 1990 |
| Cediranib | Phase 3 | Phase 3 | 1 | 0 | 1 | 10 | 0 | — | — | 2006-01 |
| Dasatinib | Phase 3 | Phase 3 | 1 | 1 | 1 | 10 | 0 | — | — | 2006-03 |
| Busulfan | Phase 3 | Phase 3 | 1 | 1 | 1 | 8 | 0 | — | — | 1998-11 |
| 5-Aminolevulinic Acid | Phase 3 | Phase 3 | 1 | 1 | 1 | 7 | 0 | — | — | 1999-10 |
| Mercaptopurine | Phase 3 | Phase 3 | 1 | 1 | 2 | 4 | 0 | — | — | 1996-08 |
| Thioguanine | Phase 3 | Phase 3 | 1 | 1 | 2 | 3 | 0 | — | — | 2003-09 |
| Daunorubicin | Phase 3 | Phase 3 | 1 | 1 | 2 | 2 | 0 | — | — | Feb 29, 2012 |
| Pegaspargase | Phase 3 | Phase 3 | 1 | 1 | 2 | 2 | 0 | — | — | Feb 29, 2012 |
| Blinatumomab | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Oct 31, 2019 |
| Calaspargase Pegol | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Oct 31, 2019 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.